| N04BA03 - Levodopa, Decarboxylase Inhibitor and Comt Inhibitor | ATC-DDD Version 2016. Source: WHO | | | N04 - Anti-Parkinson Drugs | This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.
| The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.
No separate DDDs are established for oral depot formulations.
|
| | N04B - Dopaminergic Agents | | |
| | N04BA - Dopa and Dopa Derivatives | Combinations with decarboxylase inhibitors and other dopaminergic agents are classified here.
| The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.
|
| | N04BA03 - Levodopa, Decarboxylase Inhibitor and Comt Inhibitor | | Dose | Route of administration | Note |
|---|
| | O | Refers to levodopa |
|
|
|
|
